Attenuated beta endorphin response to acute stress is associated with smoking relapse

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 3, 2008, Pages 357-362

  Shaw, Darcy ^a   al'Absi, Mustafa ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Beta endorphin; Endogenous opioid; Relapse; Smoking; Stress

Indexed keywords

BETA ENDORPHIN;

ACUTE STRESS; ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISTRESS SYNDROME; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PUBLIC SPEAKING; RELAPSE; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ACUTE DISEASE; ADULT; BETA-ENDORPHIN; COTININE; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; PSYCHOMOTOR PERFORMANCE; RECURRENCE; RISK; SMOKING; SMOKING CESSATION; SOCIAL ENVIRONMENT; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 44649119841     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.03.020     Document Type: Article

References (73)

1. al'Absi M., Bongard S., Buchanan T., Pincomb G.A., and Licinio J. Cardiovascular and neuroendocrine adjustment to public speaking and mental arithmetic stressors. Psychophysiology 34 (1997) 266-275
2. al'Absi M., Hatsukami D., and Davis G.L. Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology (Berl) 181 (2005) 107-117
3. al'Absi M., Lovallo W.R., McKey B.S., and Pincomb G.A. Borderline hypertensives produce exaggerated adrenocortical responses to mental stress. Psychosom Med 56 (1994) 245-250
4. al'Absi M., Lovallo W.R., McKey B., Sung B.H., Whitsett T.L., and Wilson M.F. Hypothalamic-pituitary-adrenocortical responses to psychological stress and caffeine in men at high and low risk for hypertension. Psychosom Med 60 (1998) 521-527
5. al'Absi M., Petersen K.L., and Wittmers L.E. Adrenocortical and hemodynamic predictors of pain perception in men and women. Pain 96 (2002) 197-204
6. al'Absi M., Wittmers L.E., Erickson J., Hatsukami D., and Crouse B. Attenuated adrenocortical and blood pressure responses to psychological stress in ad libitum and abstinent smokers. Pharmacol Biochem Behav 74 (2003) 401-410
7. Arnsten J.H., Reid K., Bierer M., and Rigotti N. Smoking behavior and interest in quitting among homeless smokers. Addict Behav 29 (2004) 1155-1161
8. Berrendero F., Kieffer B.L., and Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci 22 (2002) 10935-10940
9. Biala G., Budzynska B., and Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacol Rep 57 (2005) 755-760
10. Boyadjieva N.I., and Sarkar D.K. The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 61 (1997) PL59-PL66
11. Brown R.A., Kahler C.W., Zvolensky M.J., Lejuez C.W., and Ramsey S.E. Anxiety sensitivity: relationship to negative affect smoking and smoking cessation in smokers with past major depressive disorder. Addict Behav 26 (2001) 887-899
12. Brown R.A., Lejuez C.W., Kahler C.W., Strong D.R., and Zvolensky M.J. Distress tolerance and early smoking lapse. Clin Psychol Rev 25 (2005) 713-733
13. Cohen S., Kamarck T., and Mermelstein R. A global measure of perceived stress. J Health Soc Behav 24 (1983) 385-396
14. Cohen S., and Lichtenstein E. Perceived stress, quitting smoking, and smoking relapse. Health Psychol 9 (1990) 466-478
15. Covey L.S. Tobacco cessation among patients with depression. Prim Care 26 (1999) 691-706
16. Cox L.S., Tiffany S.T., and Christen A.G. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 3 (2001) 7-16
17. Curvall M., Elwin C.E., Kazemi-Vala E., Warholm C., and Enzell C.R. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. Eur J Clin Pharmacol 38 (1990) 281-287
18. Day J.J., and Carelli R.M. The nucleus accumbens and Pavlovian reward learning. Neuroscientist 13 (2007) 148-159
19. del Arbol J.L., Munoz J.R., Ojeda L., Cascales A.L., Irles J.R., Miranda M.T., et al. Plasma concentrations of beta-endorphin in smokers who consume different numbers of cigarettes per day. Pharmacol Biochem Behav 67 (2000) 25-28
20. Dilts R.P., and Kalivas P.W. Autoradiographic localization of mu-opioid and neurotensin receptors within the mesolimbic dopamine system. Brain Res 488 (1989) 311-327
21. Duncan C.L., Cummings S.R., Hudes E.S., Zahnd E., and Coates T.J. Quitting smoking: reasons for quitting and predictors of cessation among medical patients. J Gen Intern Med 7 (1992) 398-404
22. Epstein A.M., and King A.C. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav 77 (2004) 29-37
23. Garvey A.J., Bliss R.E., Hitchcock J.L., Heinold J.W., and Rosner B. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav 17 (1992) 367-377
24. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci 26 (2001) 304-318
25. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4 (2004) 39-50
26. Gonzales R.A., and Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18 (1998) 10663-10671
27. Gronwall D. Paced Auditory Serial Addition Task: a measure of recovery from concussion. Percept Mot Skills 44 (1997) 373
28. Guillemin R., Vargo T., Rossier J., Minick S., Ling N., Rivier C., et al. Beta-endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland. Science 197 (1977) 1367-1369
29. Hatsukami D.K., Dahlgren L., Zimmerman R., and Hughes J.R. Symptoms of tobacco withdrawal from total cigarette cessation versus partial cigarette reduction. Psychopharmacology (Berl) 94 (1988) 242-247
30. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
31. Heinz A., Rommelspacher H., Graf K.J., Kurten I., Otto M., and Baumgartner A. Hypothalamic-pituitary-gonadal axis, prolactin, and cortisol in alcoholics during withdrawal and after three weeks of abstinence: comparison with healthy control subjects. Psychiatry Res 56 (1995) 81-95
32. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 129 (1997) 99-111
33. Hughes J.R. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60 (1992) 689-697
34. Kalivas P.W., and Nakamura M. Neural systems for behavioral activation and reward. Curr Opin Neurobiol 9 (1999) 223-227
35. Kassel J.D., Stroud L.R., and Paronis C.A. Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. Psychol Bull 129 (2003) 270-304
36. Kenford S.L., Smith S.S., Wetter D.W., Jorenby D.E., Fiore M.C., and Baker T.B. Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70 (2002) 216-227
37. Khachaturian H., Dores R.M., Watson S.J., and Akil H. Beta-endorphin/ACTH immunocytochemistry in the CNS of the lizard Anolis carolinensis: evidence for a major mesencephalic cell group. J Comp Neurol 229 (1984) 576-584
38. King A.C., and Meyer P.J. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66 (2000) 563-572
39. Koob G.F. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654 (1992) 171-191
40. Koob G.F., and Le Moal M. Drug abuse: Hedonic homeostatic dysregulation. Science 278 (1997) 52-57
41. Krishnan-Sarin S., Rosen M.I., and O'Malley S.S. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 56 (1999) 663-668
42. Laviolette S.R., Nader K., and van der Kooy D. Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes. Behav Brain Res 129 (2002) 17-29
43. Laviolette S.R., and van der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry 8 (2003)
44. Lutfy K., Brown M.C., Nerio N., Aimiuwu O., Tran B., Anghel A., et al. Repeated stress alters the ability of nicotine to activate the hypothalamic-pituitary-adrenal axis. J Neurochem 99 (2006) 1321-1327
45. Mansour A., Khachaturian H., Lewis M.E., Akil H., and Watson S.J. Anatomy of CNS opioid receptors. Trends Neurosci 11 (1988) 308-314
46. Marchesi C., Chiodera P., Ampollini P., Volpi R., and Coiro V. Beta-endorphin, adrenocorticotropic hormone and cortisol secretion in abstinent alcoholics. Psychiatry Res 72 (1997) 187-194
47. Nisell M., Nomikos G.G., and Svensson T.H. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 75 (1994) 348-352
48. Olive M.F., Koenig H.N., Nannini M.A., and Hodge C.W. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci 21 (2001) RC184
49. Oswald L.M., and Wand G.S. Opioids and alcoholism. Physiol Behav 81 (2004) 339-358
50. Owens P.C., and Smith R. Opioid peptides in blood and cerebrospinal fluid during acute stress. Baillieres Clin Endocrinol Metab 1 (1987) 415-437
51. Pecina S., and Berridge K.C. Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness?. J Neurosci 25 (2005) 11777-11786
52. Perkins K.A., and Grobe J.E. Increased desire to smoke during acute stress. Br J Addict 87 (1992) 1037-1040
53. Piasecki M.P., Steinagel G.M., Thienhaus O.J., and Kohlenberg B.S. An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoact Drugs 34 (2002) 301-304
54. Pomerleau O.F. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking. Am J Med 93 (1992) 2S-7S
55. Pomerleau O.F. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology. 23 (1998) 115-130
56. Pritchard W.S., Robinson J.H., and Guy T.D. Enhancement of continuous performance task reaction time by smoking in non-deprived smokers. Psychopharmacology (Berl) 108 (1992) 437-442
57. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1 (1977) 385-401
58. Rasmussen D.D. Effects of chronic nicotine treatment and withdrawal on hypothalamic proopiomelanocortin gene expression and neuroendocrine regulation. Psychoneuroendocrinology 23 (1998) 245-259
59. Rasmussen D.D., Boldt B.M., Bryant C.A., Mitton D.R., Larsen S.A., and Wilkinson C.W. Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. Alcohol Clin Exp Res 24 (2000) 1836-1849
60. Robledo P., and Koob G.F. Two discrete nucleus accumbens projection areas differentially mediate cocaine self-administration in the rat. Behav Brain Res. 55 (1993) 159-166
61. Roth-Deri I., Zangen A., Aleli M., Goelman R.G., Pelled G., Nakash R., et al. Effect of experimenter-delivered and self-administered cocaine on extracellular beta-endorphin levels in the nucleus accumbens. J Neurochem 84 (2003) 930-938
62. Rukstalis M., Jepson C., Strasser A., Lynch K.G., Perkins K., Patterson F., et al. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl) 180 (2005) 41-48
63. Salamone J.D. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res 61 (1994) 117-133
64. Scanlon M.N., Lazar-Wesley E., Grant K.A., and Kunos G. Proopiomelanocortin messenger RNA is decreased in the mediobasal hypothalamus of rats made dependent on ethanol. Alcohol Clin Exp Res 16 (1992) 1147-1151
65. Self D.W., and Nestler E.J. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend 51 (1998) 49-60
66. Sherman E., Strauss E., and Spellacy F. Validity of the Paced Auditory Serial Addition Test (PASAT) in adults referred for neuropsychological assessment after head injury. Clin Neuropsychol 11 (1997) 34-35
67. Smith R., Owens P.C., Lovelock M., Chan E.C., and Falconer J. Acute hemorrhagic stress in conscious sheep elevates immunoreactive beta-endorphin in plasma but not in cerebrospinal fluid. Endocrinology 118 (1986) 2572-2576
68. Spielberger C.D., Gorsuch R., and Lushene R. State-trait anxiety manual (1983), Consulting Psychological Press, Palo Alto, CA
69. Stitzer M.L., and Gross J. Smoking relapse: the role of pharmacological and behavioral factors. Prog Clin Biol Res 261 (1988) 163-184
70. Swan G.E., Ward M.M., and Jack L.M. Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav 21 (1996) 481-490
71. Walters C.L., Cleck J.N., Kuo Y.C., and Blendy J.A. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron. 46 (2005) 933-943
72. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol 5 (2005) 9-19
73. Wewers M.E., Tejwani G.A., and Anderson J. Plasma nicotine, plasma beta-endorphin and mood states during p`eriods of chronic smoking, abstinence and nicotine replacement. Psychopharmacology (Berl) 116 (1994) 98-102